| The publications listed on this website are provided as a courtesy only. The listed publications reference BioCryst drugs that are investigational in the U.S., meaning that they have not been approved or determined to be safe and effective by the FDA and are not commercially available in the U.S. |
Clinical Publications
Hernandez JE, Grainger J, Simonsen L, Collis P, Edelman L, Sheridan W. Impact of the 2009/10 influenza A (H1N1) pandemic on trends in influenza hospitalization, diagnostic testing, and treatment. Influenza Other Respi Viruses. Epub ahead of print. Article
Scheetz MH, Griffith M, Ghossein C, Hollister AS, Ison MG. Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration. Ann Pharmacother 2011 Nov 24. Epub ahead of print. Article
Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic A (H1N1) influenza virus infection. Antimicrob Agents Chemother 2011, Epub ahead of print. Article
Saumil Doshi, et al. Description of Antiviral Treatment Among Adults Hospitalized With Influenza Before and During the 2009 Pandemic: United States, 2005–2009. J Infect Dis. 2011;204:1848-56. Article
Hernandez JE, Ison MG, Atiee G, Kohno S, Alexander JW, Elder J, et al. Antiviral susceptibility of influenza viruses after therapy (Rx) with peramivir (PVR) vs. placebo (PBO) or oseltamivir (OSE) in influenza subjects in Phase 2 and 3 trials. Presented at the ISIRV Conference Influenza Anti-virals: Efficacy and Resistance. 2011 Nov 8-10. Rio de Janeiro, Brazil. Abstract, Poster & Slide Presentation
Atiee G, Laughlin A, Tellier G, Collis P, Alexander WJ, Wise JM, et al. Virologic analysis of influenza viruses after therapy with a single intramuscular (IM) dose of the neuraminidase inhibitor (NAI) peramivir (PVR) versus placebo (PBO) in patients with influenza in the outpatient (OP) setting. Presented at the 49th Annual Meeting of the Infectious Diseases Society of America. 2011 Oct 20-23. Boston, Massachusetts. Abstract & Poster Presentation
Yoshida R, Kohno S, Kida H, Sugaya N. Neuraminidase sequence analysis and susceptibilities to neuraminidase (NA) inhibitors of influenza virus isolated from peramivir clinical studies. Presented at the International Union of Microbiological Societies Congress. 2011 Sept 11-16. Sapporo, Japan. Abstract & Poster Presentation
Abed Y, Boivin G, Yoshida R, Kodama M, Hernandez JE. Parenteral peramivir treatment for oseltamivir-resistant 2009 pandemic influenza A H1N1 viruses [letter]. J Infect Dis. 2011; 204:1641-42. Article
Memoli MJ, Davis AS, Proudfoot K, Chertow DS, RJ Hrabal, Bristol T, et al. Reply to Abed et al [letter]. J Infect Dis. 2011; 204: 1642-43. Article
Atiee G, Lasseter K, Baughman S, McCullough A, Collis P, Hollister A, et al. Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans. J Clin Pharmacol 2011 Sept 29. Epub ahead of print. Article
Ison MG, O’Neil B, Elder J, Collis P, Hernandez JE: Safety and Antiviral Effect of Multi-Day Therapy with IV Peramivir 300mg BID or 600mg QD in Hospitalized Influenza Subjects - Presented at the 51st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2011 Sept 17-20; Chicago, Illinois. Abstract & Slide Presentation
Ison M, Hui D, Collis P, Alexander J, Flynt A, Hernandez J: No Evidence of Resistance in Influenza Viruses After 5-Day IV Peramivir Therapy in Hospitalized Patients - Presented at the 51st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2011 Sept 17-20; Chicago, Illinois. Abstract & Poster Presentation
Ison MG, Riordan W, Elder J, Collis P, Hernandez JE: Comparison of Tissue Culture Infective Dose (TCID50) and Quantitative PCR (QPCR) in the diagnosis and follow up of influenza in hospitalized subjects - Presented at the 51st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2011 Sept 17-20; Chicago, Illinois. Abstract & Poster Presentation
Clay PG, Adiga RB, Taylor TA, Alsup R, Gerk PM, McRae M. Postpartum pharmacokinetics of peramivir in the treatment of 2009 H1N1 influenza. Obstet Gynecol 2011; 118:463-7. Article
Fry AM, Perez A, Finelli L. Use of intravenous neuraminidase inhibitors during the 2009 pandemic: results from population-based surveillance [research letter]. JAMA 2011;306:160-162. Article
Shetty AK, Ross GA, Pranikoff T, Gubareva LV, Sechrist C, Guirand DM, et al. Oseltamivir-resistant 2009 H1N1 influenza pneumonia during therapy in a renal transplant recipient. Pediatr Transplantation 2011. DOI: 10.1111/j.1399-3046.2011.01489.x Article
Ison MG. Update on IV peramivir phase 3 trials. Presented at the XIII International Symposium Respiratory Viral Infections (ISRVI); 2011 Mar 13; Rome, Italy. Slide Presentation
Hernandez J, Flynt A, Kohno S, Dobo S, Sheridan W; Peramivir Study Groups. Analyses of markers of liver injury in phase 2 and 3 controlled clinical trials of peramivir in subjects with influenza infection -- Presented at the XIII International Symposium on Respiratory Viral Infections (ISRVI); 2011 Mar 13; Rome, Italy. Abstract & Poster Presentation
Hernandez JE, Adiga R, Armstrong R, Bazan J, Bonilla H, Bradley J, et al; eIND Peramivir Investigators. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an emergency IND program in the United States. Clin Infect Dis. 2011;52:695-706. Article
Jain S, Fry AM. Peramivir: Another tool for influenza treatment? Clin Infect Dis. 2011;52:707-709. Article
Kohno S, Kida H, Mizuguchi M, Hirotsu N, Ishida T, Kadota J, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother. 2011;55:2803-2812. Article
Sugaya N, Shinjoh M, Mitamura K, Takahashi t. Very Low Pandemic Influenza A (H1N1) 2009 Mortality Associated with Early Neuraminidase Inhibitor Treatment in Japan: Analysis of 1000 Hospitalized Children. J Infect. 2011;doi:10.1016/j.jinf.2011.06.008. Article
Hollister AS, Sheridan WP. The emergency use authorization of peramivir IV: a view from the manufacturer. Clin Pharmacol Ther. 2011;89:172-4. Article
Lee BY, Tai JHY, Bailey RR, McGlone SM, Wiringa AE, Zimmer SM, et al. Economic model for Emergency Use Authorization of intravenous peramivir. Am J Manag Care. 2011;17:e1-e9. Article
Arya V, Carter WW, Robertson SM. The role of clinical pharmacology in supporting the Emergency Use Authorization of an unapproved anti-influenza drug, peramivir. Clin Pharmacol Ther. 2010;88:587-589. Article
Nasu T, Ogawa D, Wada J, Makino H. Peramivir for severe influenza infection in a patient with diabetic nephropathy [letter]. Am J Resp Crit Care Med. 2010;182:1209-10. Article
Hernandez J, Alexander W, Kohno S, Elder J, Sheridan W; Peramivir Study Groups. Neutropenia is not related to neuraminidase inhibitor (NAI) therapy of uncomplicated influenza in phase 2 and 3 controlled clinical trials – Presented at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA); 2010 Oct 21-24; Vancouver, British Columbia, Canada. Abstract & Poster Presentation
Ison M, Hui DSC, Sebastian PJ, Flynt A, Collis P, Alexander W, et al. Clinical and virologic outcomes with peramivir therapy in hospitalized adults with influenza B: sub-group analysis of a phase 2 trial – Presented at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA); 2010 Oct 21-24; Vancouver, British Columbia, Canada. Abstract & Poster Presentation
Bazan JA, Bauer KA, Hollister AS, Shidham G, Firstenberg MS, Reed EE, et al. Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy. Pharmacotherapy. 2010;30:1016-20. Article
Sorbello AF, Jones SC, Carter W, Struble K; Peramivir Safety Team. Safety of peramivir accessed under the FDA Emergency Use Authorization (EUA) to treat hospitalized patients infected with 2009 H1N1 influenza virus -- Presented at the 50th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2010 Sept 12-15; Boston, Massachusetts. Abstract
Lasseter K, Atiee G, Baughman S, McCullough A, Collis P, Hollister A, et al. No pharmacokinetic (PK) interactions observed between intravenous (IV) peramivir and oral (PO) oseltamivir or rimantadine in humans – Presented at the 50th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2010 Sept 12-15; Boston, Massachusetts. Abstract & Poster Presentation
Satin L, Haugen G, Waugh A, Collis P, Hernandez J, Hollister; BioCryst Pharmaceuticals Protocol BCX1812-106. Intravenous (IV) peramivir was not associated with repolarization abnormalities in a thorough QT/QTc electrocardiographic (ECG) study – Presented at the 50th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2010 Sept 12-15; Boston, Massachusetts. Abstract & Poster Presentation
Tanaka T, Nagai Y. Serum antibody titers against influenza virus in pediatric patients after treating with peramivir -- Presented at the VII Options for the Control of Influenza; 2010 Sept 3-7; Hong Kong SAR, China. Abstract & Poster Presentation
Sugaya N, Kohno S, Takahashi T. Efficacy and safety of intravenous peramivir in children with 2009 pandemic A (H1N1) influenza virus infection – Presented at the International Conference on Emerging Infectious Diseases (ICEID); 2010 July 11-14; Atlanta, Georgia, and at the VII Options for the Control of Influenza; 2010 Sept 3-7; Hong Kong SAR, China. Abstract & Poster Presentation
Kohno S, Kida H, Mizuguchi M, Shimada J; S-021812 Clinical Study Group. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54:4568-74. Article
Kohno S, Yen MY, Cheong JH, Hirotsu N, Ishida T, Kadota J, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011; 55:5267-5276 Article
Campbell AP, Jacob ST, Kuypers J, Wald A, Englund JA, Corey L, et al. Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: Detection of extrapulmonary H1N1 RNA and use of intravenous peramivir. Ann Intern Med. 2010;152:619-20. Article
Thomas B, Hollister AS, Muczynski KA. Peramivir clearance in continuous renal replacement therapy [letter]. Hemodial Int. 2010;14:339-40. Epub 2010 May 18. Article
Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362:1708-1719. Article
Hernandez J, Hollister A, Sheridan W; Peramivir eIND Investigator Group. A review of clinical experience in the treatment of severe 2009 H1N1 influenza with intravenous peramivir under an emergency Investigational New Drug (IND) program in the United States - Presented at the XII International Symposium on Respiratory Viral Infections (ISRVI); 2010 Mar 11-14; Taipei, China. Abstract & Slide Presentation
Hernandez JE. Peramivir advanced clinical development update. Presented at the XII International Symposium Respiratory Viral Infections (ISRVI); 2010 Mar 11-14; Taipei, China. Slide Presentation
Nakanishi H, Muta T, Fujisaki T, Yoshitomi R, Kubo T, Yokota E. Pandemic (H1N1) 2009-associated ARDS rescued by neuraminidase inhibitors with emergency use of extracorporeal membrane oxygenation. Inter Med. 2010;49:1901-1905. Article
Birnkrant D, Cox E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med. 2009;361:2204-7. Epub 2009 Nov 2. Article
Swan S, Marbury T, Smith W, Levasseur L, Elder J, Alexander W, et al. Safety and pharmacokinetics of peramivir following intravenous administration in subjects with renal impairment – Presented at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA); 2009 Oct 29-Nov 1; Philadelphia, Pennsylvania. Abstract & Poster Presentation
Ison MG, McGeer AJ, Hui DS, Clezy K, O’Neil B, Flynt A, et al. Safety and efficacy of multiple-day treatment with intravenous peramivir or oral oseltamivir in hospitalized adults with acute influenza -- Presented at the XI International Symposium on Respiratory Viral Infections (ISRVI); 2009 Feb 19-22; Bangkok, Thailand. Abstract & Slide Presentation
Kohno S, Kida H, Mizuguchi M, Shimada J; S-021812 Clinical Study Group. A double-blind, placebo-controlled study of intravenous peramivir in acute influenza patients – Presented at the 48th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2008 Sept 25-28; Washington DC. Abstract & Poster Presentation
Alexander WJ, Harman LA, Collis PJ, Elder J, Kilpatrick JM, Atiee G, et al. Nasal and pharyngeal concentrations of peramivir following intramuscular and intravenous administration in healthy volunteers -Presented at the 47th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2007 Sept 17-20; Chicago, Illinois. Abstract & Poster Presentation
Beigel J, Harman LA, Collis PJ, McCullough A, Kilpatrick JM, Ruff D, et al. Pharmacokinetic and safety evaluations of escalating doses of peramivir administered intravenously in healthy volunteers -Presented at the 47th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2007 Sept 17-20; Chicago, Illinois. Abstract & Poster Presentation
Collis PJ, Harman LA, Kilpatrick JM, Denoia E, Mead E, Noonan P, et al. A placebo-controlled evaluation of the safety and pharmacokinetics of multiple-dose intravenous administration of peramivir to healthy elderly subjects -Presented at the 47th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2007 Sept 17-20; Chicago, Illinois. Abstract & Poster Presentation
Other Publications
Bromba CM, Mason JW, Brant MG, Chan T, Lunke MD, Petric M, et al. The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase. Bioorg Med Chem Lett 2011; Dec 1;21(23):7137-7141. Epub 2011 Sep 24. Article
Boivin G, Abed Y. Peramivir Retains Therapeutic Activity Against the Influenza A/H1N1 H275Y Mutant in a Mouse Model.. Presented at the ISIRV Conference Influenza Anti-virals: Efficacy and Resistance. 2011 Nov 8-10. Rio de Janeiro, Brazil. Abstract
Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, et al. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses 2010; 2:2269-2289. Article
Kitano M, Kodama M, Baba K, Noda T, Kakui M, Iwasaki H, et al. Efficacy of a single intravenous injection of peramivir (BCX-1812) compared to oral oseltamivir against seasonal influenza B virus infection in ferrets. Presented at the International Union of Microbiological Societies 2011 Congress. 2011 Sept 11-16. Sapporo, Japan. Abstract & Poster Presentation
Takeshi N, Kitano M, Kodama M, Yoshida R, Sato A. Therapeutic effect of peramivir (BCX-1812) after single intravenous infusion in mice infected with influenza A virus with H274Y mutated NA. Presented at the International Union of Microbiological Societies 2011 Congress. 2011 Sept 11-16. Sapporo, Japan. Abstract & Poster Presentation
Kodama M, Noshi T, Kobayashi M, Yoshida R, Sato A, Nomura N, et al. Antiviral efficacy of peramivir (BCX-1812) against highly pathogenic avian influenza viruses (H5N1) with or without the H274Y mutation in mouse. Presented at the International Union of Microbiological Societies 2011 Congress. 2011 Sept 11-16. Sapporo, Japan. Abstract & Poster Presentation
Sugaya N. Widespread use of neuraminidase inhibitors in Japan. J Infect Chemother 2011; 17:595-601. Article
Barrett S, Mohr PG, Schmidt PM, McKimm-Breschkin JL. Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses. PLoS One 2011;6(8):e23627. Epub 2011 Aug 17. Article
Kitano M, Itoh Y, Kodama M, Ishigaki H, Nakayama M, Ishida H, et al. Efficacy of single intravenous injectionof peramivir against influenza B virus infection in ferrets and cynomolgus macaques. Antimicrob Agents Chemother 2011; 55:4961-70. Article
Bantia S, Upshaw R, Babu Y.S. Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme. Antivir Res 2011; 91:288-291 Article
Hurt AC, Lee RT, Leang SK, Cui L, Deng YM, Phuah SP, et al. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 2011;16(23):pli=19884. Article
Bantia S, Kellogg D, Parker C, Upshaw R, Ilyushina NA, Babu YS. A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice. Antivir Res. 2011;901:17-21. Epub 2011 Feb 21. Article
Pizzorno A, Bouhy X, Abed Y, Boivin G. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis. 2011;203:25-31. Article
Martin AR, Collins CD, Otto M, Malani A, Cinti S. Peramivir, a new drug for influenza. Infect Dis Clin Pract. 2011;19:11-15. Article
Bantia S, Kellogg D, Parker CD, Babu YS. Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model. Antivir Res. 2010;88:276-80. Epub 2010 Oct 11. Article
Yoshida R, Izawa M, Kitano M, Kodama M, Sato A. Therapeutic effects of peramivir after intravenous treatment on immunosuppressed mice infected with influenza A virus – Presented at the VII Options for the Control of Influenza; 2010 Sept 3-7; Hong Kong SAR, China. Abstract & Poster Presentation
Kitano M, Itoh Y, Kodama M, Yoshida R, Ishigaki H, Nakayama M, et al. Evaluation of effects of peramivir against seasonal influenza B virus infection in Cynomolgus macaques – Presented at the VII Options for the Control of Influenza; 2010 Sept 3-7; Hong Kong SAR, China. Abstract & Poster Presentation
Boltz DA, Aldridge Jr JR, Webster RG, Govorkova EA. Drugs in development for influenza. Drugs 2010;70:1349-1362. Article
Stoner TD, Krauss S, DuBois RM, Negovetich NJ, Stallknecht DE, Senne DA, et al. Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype. J Virol. 2010;84:9800-9809. Article
Smee DF, Hurst BL, Wong MH, Tarbet EB, Babu YS, Klumpp K, et al. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antivir Res. 2010;88:38-44. Epub 2010 Jul 13. Article
Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother. 2010;54:3671-3677. Epub 2010 Jun 28. Article
Bantia S, Kellogg D, Parker C, Luo Y, Babu YS. Combination of peramivir and rimantadine demonstrates synergistic anti-influenza effects in an influenza A mouse model – Presented at the International Conference on Antiviral Research (ICAR); 2010 Apr 25-28; San Francisco, California. Abstract & Poster Presentation
Bantia S, Kellogg D, Parker C, Upshaw R, Ilyushina N, Prichard M, et al. A single intramuscular injection of peramivir demonstrates anti-influenza activity against recently isolated pandemic flu virus H1N1 (A/CA/04/2009) in a mouse influenza model – Presented at the International Conference on Antiviral Research (ICAR); 2010 Apr 25-28; San Francisco, California. Abstract & Poster Presentation
Smee D, Hurst B, Wong M-H, Tarbet EB, Babu YS, Morrey J. Efficacy of combinations of oseltamivir and peramivir in treating influenza a (H1N1) virus infections in cell culture and in mice – Presented at the International Conference on Antiviral Research (ICAR); 2010 Apr 25-28; San Francisco, California. Abstract & Poster Presentation
Tarbet B, Hurst B, Barnard D, Babu YS, Furuta Y, Smee D. Antiviral drug efficacy evaluation against pandemic influenza a (H1N1) viruses in MDCK cells – Presented at the International Conference on Antiviral Research (ICAR); 2010 Apr 25-28; San Francisco, California. Abstract & Poster Presentation
Abed Y, Simon P, Boivin G. Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation. Antimicrob Agents Chemother. 2010;54:2819-22. Epub 2010 Apr 19. Article
Castillo R, Holland LE, Boltz DA. Peramivir and its use in H1N1 influenza. Drugs Today 2010;46:399-408. Article
Mancuso CE, Gabay MP, Steinke LM, VanOsdol SJ. Peramivir: An intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza. Ann Pharmacother. 2010;44:1240-1249. Article
Gubareva LV, Trujillo AA, Okomo-Adhiambo M, Mishin VP, Deyde VM, Sleeman K, et al. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther. 2010;15(8):1151-9. Article
Kobayashi M, Isoda N, Kodama M, Yoshida R, Sato A, Yamano Y, et al. Inhibitory effect of peramivir (S-021812, BCX-1812) against highly pathogenic avian influenza viruses – Presented at the 49th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2009 Sept 12-15; San Francisco, California. Abstract & Poster Presentation
Yoshida R, Kodama M, Kobayashi M, Kitano M, Sato A, Yamano Y. Therapeutic effect of peramivir (S-021812, BCX-1812) after single intravenous treatment of mice infected with influenza A and B viruses – Presented at the 49th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2009 Sept 12-15; San Francisco, California. Abstract & Poster Presentation
Hurt AC, Deng EJ, Iannella P, Besselaar TF, Birch C, et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 2009;83:90-93. Article
Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother. 2009;53:4433-4440. Article
Baz M, Abed Y, Boivin G. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antivir Res. 2007;74:159-162. Article
Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antivir Res. 2006;69:39-45. Article
Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antiv Ther. 2006;11:971-976. Article